Brigatinib (Alunbrig ®) is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/11/2018|
|Rapid review completed||11/12/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
The HSE has approved reimbursement following confidential price negotiations; June 2019